Xeljanz Approved for Treatment of Rheumatoid Arthritis
Release Date: November 15, 2012
The U.S. Food and Drug Administration (FDA) recently approved Xeljanz (tofacitinib) for the treatment of moderate to severe rheumatoid arthritis. This is the first oral medication to be approved by the FDA for this condition in more than 10 years. Xeljanz will be commercially available in pharmacies on or around November 19, 2012.
Blue Cross and Blue Shield of North Carolina (BCBSNC) will add Xeljanz to our pharmacy utilization management program, which means this drug, will require prior review and be subject to a quantity limitation when prescribed to commercial members who have their pharmacy benefits with us.
These requirements will not apply to State Health Plan, Federal Employee Program, or Medicare Part D members, or for any employer groups that carve out their pharmacy benefits to another pharmacy benefits manager. Detailed criteria can be found online at bcbsnc.com.
If you have questions, please contact the Provider Blue LineSM at 1.800.214.4844.